If you have been researching Sermorelin vs CJC-1295, you have likely encountered two very different types of information: older content describing CJC-1295 as an effective and widely available peptide, and more recent information suggesting it is no longer accessible. Both are correct, depending on when that content was written. The regulatory landscape for peptide therapy
One of the first questions people ask before starting HGH therapy is how long it takes to see results. It is a reasonable question, and the honest answer is that the timeline depends on what you are measuring. Some changes happen within the first few weeks. Others require six months or more of consistent therapy.
Low testosterone in women is one of the most commonly missed hormonal diagnoses in female healthcare. Most conversations about testosterone focus on men, yet testosterone is a critical hormone for women at every stage of adult life. It affects energy, libido, body composition, cognitive clarity, bone density, and mood. When levels fall below the range
The connection between belly fat and cortisol, the body’s primary stress hormone, is one of the most clinically documented and most frequently overlooked factors in weight management. You may eat reasonably well, exercise regularly, and still find stubborn abdominal fat that will not shift. When conventional approaches fail, chronic cortisol elevation is often the missing
Erectile dysfunction affects an estimated 30 million men in the United States, yet the majority of cases are never fully evaluated. Many men are told to reduce stress, exercise more, or simply accept that changes in sexual function are a normal part of aging. While lifestyle and psychological factors do play a role, a significant
CJC-1295 and Ipamorelin are two synthetic peptides that work together to stimulate the pituitary gland’s own release of growth hormone. When used as a combination protocol, they support muscle recovery, tissue regeneration, and body composition in adults with age-related or clinically confirmed growth hormone decline — without replacing GH directly. ~14% Decline in GH secretion
